Evidence map›Paper›PMID 26225919›Full record

ArticlePloS one2015

The Drosophila Transcription Factors Tinman and Pannier Activate and Collaborate with Myocyte Enhancer Factor-2 to Promote Heart Cell Fate.

TyAnna L Lovato, Cheryl A Sensibaugh, Kirstie L Swingle, Melody M Martinez, Richard M Cripps

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Drosophila as a Model to Understand Second Heart Field Development.Journal of cardiovascular development and disease · 2023
    Review
  3. Article
  4. Article
  5. The Molecular Properties and Roles ofFrontiers in physiology · 2022
    Article
  6. Article
  7. Heart Development and Regeneration in Non-mammalian Model Organisms.Frontiers in cell and developmental biology · 2020
    Review
  8. Article
  9. Article
  10. Genome-Wide Approaches to Drosophila Heart Development.Journal of cardiovascular development and disease · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

TyAnna L LovatoDepartment of Biology, University of New Mexico, Albuquerque, NM 87131-1091, United States of America.
Cheryl A SensibaughDepartment of Biology, University of New Mexico, Albuquerque, NM 87131-1091, United States of America.
Kirstie L SwingleDepartment of Biology, University of New Mexico, Albuquerque, NM 87131-1091, United States of America.
Melody M MartinezDepartment of Biology, University of New Mexico, Albuquerque, NM 87131-1091, United States of America.
Richard M CrippsDepartment of Biology, University of New Mexico, Albuquerque, NM 87131-1091, United States of America.
University of New Mexico · US

Funding

UNM Initiative to Maximize Student Diversity (IMSD)R25GM060201 · NIGMS · UNIVERSITY OF NEW MEXICO · PI WERNER-WASHBURNE, MARGRET C. · 2000 to 2017
$9.9M
GENETIC REGULATION OF MUSCLE FIBER DIVERSITYR01GM061738 · NIGMS · UNIVERSITY OF NEW MEXICO · PI CRIPPS, RICHARD MATTHEW · 2001 to 2022
$6.4M
Pilot Project ProgramP30GM110907 · NIGMS · UNIVERSITY OF NEW MEXICO · PI MILLER, ROBERT D · 2014 to 2018
$5.4M
COBRE Center for Evolutionary and Theoretical ImmunologyP20GM103452 · NIGMS · UNIVERSITY OF NEW MEXICO · PI LOKER, ERIC SAMUEL · 2012 to 2013
$4.2M
NIGMS NIH HHS P20 GM103452NIGMS NIH HHS P30 GM110907NIGMS NIH HHS R01 GM061738NIGMS NIH HHS R25 GM060201
6 · The paper itself

Abstract

Expression of the MADS domain transcription factor Myocyte Enhancer Factor 2 (MEF2) is regulated by numerous and overlapping enhancers which tightly control its transcription in the mesoderm. To understand how Mef2 expression is controlled in the heart, we identified a late stage Mef2 cardiac enhancer that is active in all heart cells beginning at stage 14 of embryonic development. This enhancer is regulated by the NK-homeodomain transcription factor Tinman, and the GATA transcription factor Pannier through both direct and indirect interactions with the enhancer. Since Tinman, Pannier and MEF2 are evolutionarily conserved from Drosophila to vertebrates, and since their vertebrate homologs can convert mouse fibroblast cells to cardiomyocytes in different activator cocktails, we tested whether over-expression of these three factors in vivo could ectopically activate known cardiac marker genes. We found that mesodermal over-expression of Tinman and Pannier resulted in approximately 20% of embryos with ectopic Hand and Sulphonylurea receptor (Sur) expression. By adding MEF2 alongside Tinman and Pannier, a dramatic expansion in the expression of Hand and Sur was observed in almost all embryos analyzed. Two additional cardiac markers were also expanded in their expression. Our results demonstrate the ability to initiate ectopic cardiac fate in vivo by the combination of only three members of the conserved Drosophila cardiac transcription network, and provide an opportunity for this genetic model system to be used to dissect the mechanisms of cardiac specification.

Indexed as

Amino Acid SequenceAnimalsAnimals, Genetically ModifiedBasic Helix-Loop-Helix ProteinsBinding SitesConsensus SequenceDrosophila melanogasterDrosophila ProteinsEnhancer Elements, GeneticGene Expression Regulation, DevelopmentalGenes, InsectHeartMiceMolecular Sequence DataMyocardiumMyogenic Regulatory FactorsBasic Helix-Loop-Helix ProteinsDrosophila ProteinsHand protein, DrosophilaMef2 protein, DrosophilaMyogenic Regulatory Factorspnr protein, DrosophilaRepressor Proteinssulfonylurea receptor, DrosophilaSulfonylurea Receptorstin protein, DrosophilaTrans-ActivatorsTranscription Factors

Identifiers

PMID26225919
PMCPMC4520567
OpenAlexW1681270309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.